Longboard Pharmaceuticals Inc

NASDAQ:LBPH   3:59:53 PM EDT
9.69
+0.55 (+6.02%)
Products, Regulatory

Longboard Pharmaceuticals Successfully Completes Lp352 Multiple Ascending Dose Portion Of Phase 1 Clinical Trial In Healthy Volunteers, Plans To Initiate Phase 1B/2A Clinical Trial

Published: 09/08/2021 11:40 GMT
Longboard Pharmaceuticals Inc (LBPH) - Longboard Pharmaceuticals Successfully Completes Lp352 Multiple Ascending Dose Portion of Phase 1 Clinical Trial in Healthy Volunteers, Plans to Initiate Phase 1b/2a Clinical Trial.
Longboard Pharmaceuticals Inc - Central 5-ht2c Receptor Engagement Demonstrated by Dose- and Exposure-dependent Increases of Prolactin.
Longboard Pharma - Plans to Initiate Phase 1b/2a Clinical Trial in Adult Participants With Developmental and Epileptic Encephalopathies in Q1 2022.